Background/Aim: The environmental obesogen hypothesis proposes that exposure to endocrine disruptors during developmental “window” contributes to adipogenesis and the development of obesity. Implication of environmental endocrine disruptor such as 4Nonylphenol (4-NP) on adipose tissue development has been poorly investigated. Methods:3T3-L1 preadipocytes were incubated with different doses of 4-NP. Six-week-old C57BL/6J male mice received an intraperitoneal injection of vehicle, troglitazone or 4-NP (0.5 mg/kg). Gene expression of adipogenic regulators was analyzed. Pregnant mice were dosed by gavage with vehicle or 4-NP (0.05, 0.25 or 0.5 mg/kg) from day 12 of gestation until day 7 of lactation. The body weight, liver weight, fat mass, and serum lipids and glucose levels were measured in offspring at postnatal day 60. Results: Low concentration of 4-NP induced adipocyte differentiation, glycerol-3-phosphate dehydrogenase activity, and expression of peroxisome proliferator-acivated receptor γ as well as its target genes required for adipogenesis. 4-NP perturbed key regulators of adipogenesis and lipogenic pathway in vivo. Perinatal exposure to 4-NP increased body weight, fat mass, and serum total cholesterol and glucose levels in offspring. Conclusions:4-NP may be expected to increase the incidence of obesity and can act as a potential chemical stressor for obesity and obesity-related disorders.

Keywords:
4-Nonylphenol (4-NP), Adipocyte differentiation, Peroxisome proliferator-acivated receptor γ (PPARγ), Perinatal exposure, Obesity
This content is only available via PDF.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.